Surviving The Microbiome Market with MaaT Pharma's Hervé Affagard
Business Of Biotech
00:00
How Investor Appetite Has Improved With Clinical Progress
Investors have more appetite as we are generating clinical data because we are less risky. But where I've seen the most change, especially since we have entered the phase three, is with the interest from the pharmaceutical company. Before that, it was difficult for the pharmaceutical company to buy a microbiome story That was difficult. Now that we are in phase three, and also now that we are expanding in 32 more, which is a very trendy therapeutic area,. We have something that we have not before. We have an incoming call. It's pretty way more comfortable as compared to what it was before.
Transcript
Play full episode
